Alterity Therapeutics-adr (ATHE) 13F Holders & Ownership Data (22 Funds, Q2 2026)

ATHE ranks #8180 out of 37507 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ATHE is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

22 institutions disclose a position in ATHE, but none treat it as a major bet — even Twin Lakes Capital Management, LLC, its most concentrated holder, allocates just 0.3% of its own portfolio to it.

Twin Lakes Capital Management, LLC has added to its ATHE position for two straight quarters, increasing it by $318.9K to reach $747.8K today.

ATHE reported a net loss of $23.4M in its latest fiscal year.

• Not yet profitable — net loss of $23.4M in the latest fiscal year
• Net income declined year over year, from -$12.1M to -$23.4M
• Operating cash flow was negative, using $22.5M in cash
• Current ratio of 14.52x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.08x equity — within a conventional range